Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
27,995,500
-
Total 13F shares
-
53,645,472
-
Share change
-
+8,104,422
-
Total reported value
-
$580,176,544
-
Put/Call ratio
-
100%
-
Price per share
-
$10.85
-
Number of holders
-
99
-
Value change
-
+$89,474,242
-
Number of buys
-
58
-
Number of sells
-
43
Institutional Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q4 2020
As of 31 Dec 2020,
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) was held by
99 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
53,645,472 shares.
The largest 10 holders included
ARK Investment Management LLC, FMR LLC, Bain Capital Life Sciences Investors, LLC, Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc., BlackRock Inc., Ally Bridge Group (NY) LLC, Samsara BioCapital, LLC, VANGUARD GROUP INC, and ORBIMED ADVISORS LLC.
This page lists
99
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.